ProjectBringing ASO therapies for A-T patients into clinics, at scale: a bench-to-bedside platform for personalized A-T…
Basic data
Title:
Bringing ASO therapies for A-T patients into clinics, at scale: a bench-to-bedside platform for personalized A-T ASO development
Duration:
01/09/2025 to 31/08/2026
Abstract / short description:
Ataxia-telangiectasia (A-T) is a genetic disease that causes loss of muscle control and balance, cancer, lung disease and immune system problems in children and young
adults, shortening their lives. The nonprofit A-T Children’s Project partners with academic and industry investigators worldwide – organizing and supporting innovative
research, conferences, clinical teams, data platforms and biomarkers – to optimize disease management strategies, develop new treatments and find a cure.
adults, shortening their lives. The nonprofit A-T Children’s Project partners with academic and industry investigators worldwide – organizing and supporting innovative
research, conferences, clinical teams, data platforms and biomarkers – to optimize disease management strategies, develop new treatments and find a cure.
Keywords:
AT-Patient
Ataxie- Telangiectasia
Neurodegenerative Diseases
ataxia
Ataxie
biomarker
Biomarker
Involved staff
Managers
Faculty of Medicine
University of Tübingen
University of Tübingen
University Department of Neurology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Local organizational units
Department of Neurology with Focus on Neurodegenerative Disorders
University Department of Neurology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Funders
Coconut Creek, Florida, United States